<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573430</url>
  </required_header>
  <id_info>
    <org_study_id>D2452L00015</org_study_id>
    <nct_id>NCT00573430</nct_id>
  </id_info>
  <brief_title>ARIA (Atacand Renoprotection In NephropAthy Pt.)</brief_title>
  <acronym>PCR</acronym>
  <official_title>A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effective dose of candesartan cilexetil for reduction of urinary protein
      excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline
      urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in
      urinary protein/creatinine ratio from baseline to the end of 28-week treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks</measure>
    <time_frame>baseline to 28 weeks</time_frame>
    <description>Decrease of urinary protein/creatinine ratio means improvement of renal disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Systolic and Diastolic Blood Pressure From Baseline</measure>
    <time_frame>baseline to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Marker (Hs-C-peptide Reactive Protein)</measure>
    <time_frame>baseline to 28 weeks</time_frame>
    <description>To evaluate how to reduce and relate with cardiovascular risk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation</measure>
    <time_frame>28 weeks</time_frame>
    <description>GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if African-American) (conventional units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events</measure>
    <time_frame>Baseline to 28 weeks</time_frame>
    <description>Prevalence of adverse events after treatment regardless causality. An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition from the signing of the informed consent, whether or not considered causally related to the product.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Non-diabetic Nephropathy With Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>8 mg oral once daily dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>16 mg oral once daily dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil 32mg</intervention_name>
    <description>32 mg oral once daily dose</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hypertension; a)135mmHg &lt; Systolic Blood Pressure &lt;180mmHg and/or 85 mmHg &lt; Diastolic
             Blood Pressure &lt;100 mmHg. or b) The subject has been treated with antihypertensive
             medication

          -  proteinuria (urinary protein/creatinine ratio between 500 mg/g and 5000 mg/g)

        Exclusion Criteria:

          -  Current serum-creatinine &gt; 265 mmol/L (&gt;3 mg/dL).

          -  Current serum-potassium &gt; 5.5 mmol/L

          -  Known hypersensitivity to angiotensin (AT)1-receptor blocker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Da Suk Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2007</study_first_submitted>
  <study_first_submitted_qc>December 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2007</study_first_posted>
  <results_first_submitted>June 17, 2010</results_first_submitted>
  <results_first_submitted_qc>June 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2011</results_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Candesartan Cilexetil</keyword>
  <keyword>Non-diabetic Nephropathy</keyword>
  <keyword>hypertension</keyword>
  <keyword>urine protein creatinine ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>155 enrolled, 27 screening failure, 128 randomized. Eligibility criteria not fulfilled meant subjects who were not fulfilled at Visit 1 or Enrolment, but screening failure subjects were who fulfilled at Visit 1, but not at Visit 2 after screening period.</recruitment_details>
      <pre_assignment_details>Total 128 patient enrolled, but among of them, 9 subjects excluded from analysis because of Withdrawal by Subject, Protocol violation, Eligibility criteria not fullfiled. You can see these number in above table. This analysis was conducted based on Intend to treat. Therefore, total analyzed number is 119, and 39, 44, 36 per arm respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Candesartan 8 mg</title>
          <description>Candesartan 8 mg oral once daily dose</description>
        </group>
        <group group_id="P2">
          <title>Candesartan 16mg</title>
          <description>Candesartan 16mg oral once daily dose</description>
        </group>
        <group group_id="P3">
          <title>Candesartan 32mg</title>
          <description>Candesartan 32mg oral once daily dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40">randomized</participants>
                <participants group_id="P2" count="45">randomized</participants>
                <participants group_id="P3" count="43">randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incorrect enrollment of randomization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Candesartan 8 mg</title>
          <description>Candesartan 8 mg oral once daily dose</description>
        </group>
        <group group_id="B2">
          <title>Candesartan 16mg</title>
          <description>Candesartan 16mg oral once daily dose</description>
        </group>
        <group group_id="B3">
          <title>Candesartan 32mg</title>
          <description>Candesartan 32mg oral once daily dose</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>19 to 70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.70" spread="11"/>
                    <measurement group_id="B2" value="46.80" spread="16"/>
                    <measurement group_id="B3" value="49.50" spread="11"/>
                    <measurement group_id="B4" value="47.3" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Analyzed efficacy data and demography data based on Intended to Treat (ITT) set. The discrepancy of “Total” and “Started Period 1” is who is excluded to the ITT set.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks</title>
        <description>Decrease of urinary protein/creatinine ratio means improvement of renal disease.</description>
        <time_frame>baseline to 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan 8 mg</title>
            <description>Candesartan 8 mg oral once daily dose</description>
          </group>
          <group group_id="O2">
            <title>Candesartan 16mg</title>
            <description>Candesartan 16mg oral once daily dose</description>
          </group>
          <group group_id="O3">
            <title>Candesartan 32mg</title>
            <description>Candesartan 32mg oral once daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks</title>
          <description>Decrease of urinary protein/creatinine ratio means improvement of renal disease.</description>
          <units>mg/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794.0" spread="1,070.10"/>
                    <measurement group_id="O2" value="639.9" spread="863.30"/>
                    <measurement group_id="O3" value="819.0" spread="823.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Systolic and Diastolic Blood Pressure From Baseline</title>
        <time_frame>baseline to 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan 8 mg</title>
            <description>Candesartan 8 mg oral once daily dose</description>
          </group>
          <group group_id="O2">
            <title>Candesartan 16mg</title>
            <description>Candesartan 16mg oral once daily dose</description>
          </group>
          <group group_id="O3">
            <title>Candesartan 32mg</title>
            <description>Candesartan 32mg oral once daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Systolic and Diastolic Blood Pressure From Baseline</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.70" spread="14.90"/>
                    <measurement group_id="O2" value="-13.30" spread="14.90"/>
                    <measurement group_id="O3" value="-16.10" spread="17.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.90" spread="13.30"/>
                    <measurement group_id="O2" value="-8.00" spread="13.30"/>
                    <measurement group_id="O3" value="-13.00" spread="14.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Marker (Hs-C-peptide Reactive Protein)</title>
        <description>To evaluate how to reduce and relate with cardiovascular risk</description>
        <time_frame>baseline to 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan 8 mg</title>
            <description>Candesartan 8 mg oral once daily dose</description>
          </group>
          <group group_id="O2">
            <title>Candesartan 16mg</title>
            <description>Candesartan 16mg oral once daily dose</description>
          </group>
          <group group_id="O3">
            <title>Candesartan 32mg</title>
            <description>Candesartan 32mg oral once daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Marker (Hs-C-peptide Reactive Protein)</title>
          <description>To evaluate how to reduce and relate with cardiovascular risk</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.12"/>
                    <measurement group_id="O2" value="-0.17" spread="1.86"/>
                    <measurement group_id="O3" value="-0.01" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation</title>
        <description>GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if African-American) (conventional units)</description>
        <time_frame>28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan 8 mg</title>
            <description>Candesartan 8 mg oral once daily dose</description>
          </group>
          <group group_id="O2">
            <title>Candesartan 16mg</title>
            <description>Candesartan 16mg oral once daily dose</description>
          </group>
          <group group_id="O3">
            <title>Candesartan 32mg</title>
            <description>Candesartan 32mg oral once daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated GFR Predicted From the Modification of Diet in Renal Disease (MDRD) Equation</title>
          <description>GFR (mL/min/1.73 m2) = 186 x (Scr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if African-American) (conventional units)</description>
          <units>mL/min/1.73 m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="8.45"/>
                    <measurement group_id="O2" value="1.20" spread="9.31"/>
                    <measurement group_id="O3" value="0.56" spread="8.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Adverse Events</title>
        <description>Prevalence of adverse events after treatment regardless causality. An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition from the signing of the informed consent, whether or not considered causally related to the product.</description>
        <time_frame>Baseline to 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan 8 mg</title>
            <description>Candesartan 8 mg oral once daily dose</description>
          </group>
          <group group_id="O2">
            <title>Candesartan 16mg</title>
            <description>Candesartan 16mg oral once daily dose</description>
          </group>
          <group group_id="O3">
            <title>Candesartan 32mg</title>
            <description>Candesartan 32mg oral once daily dose</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Adverse Events</title>
          <description>Prevalence of adverse events after treatment regardless causality. An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition from the signing of the informed consent, whether or not considered causally related to the product.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Candesartan 8 mg</title>
          <description>Candesartan 8 mg oral once daily dose</description>
        </group>
        <group group_id="E2">
          <title>Candesartan 16mg</title>
          <description>Candesartan 16mg oral once daily dose</description>
        </group>
        <group group_id="E3">
          <title>Candesartan 32mg</title>
          <description>Candesartan 32mg oral once daily dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pnuemonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 7780 956181 ext 5895</phone>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

